<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35793922</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Jul</Month><Day>06</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Deriving and validating a risk prediction model for long COVID-19: protocol for an observational cohort study using linked Scottish data.</ArticleTitle><Pagination><StartPage>e059385</StartPage><MedlinePgn>e059385</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e059385</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2021-059385</ELocationID><Abstract><AbstractText Label="INTRODUCTION">COVID-19 is commonly experienced as an acute illness, yet some people continue to have symptoms that persist for weeks, or months (commonly referred to as 'long-COVID'). It remains unclear which patients are at highest risk of developing long-COVID. In this protocol, we describe plans to develop a prediction model to identify individuals at risk of developing long-COVID.</AbstractText><AbstractText Label="METHODS AND ANALYSIS">We will use the national Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) platform, a population-level linked dataset of routine electronic healthcare data from 5.4&#x2009;million individuals in Scotland. We will identify potential indicators for long-COVID by identifying patterns in primary care data linked to information from out-of-hours general practitioner encounters, accident and emergency visits, hospital admissions, outpatient visits, medication prescribing/dispensing and mortality. We will investigate the potential indicators of long-COVID by performing a matched analysis between those with a positive reverse transcriptase PCR (RT-PCR) test for SARS-CoV-2 infection and two control groups: (1) individuals with at least one negative RT-PCR test and never tested positive; (2) the general population (everyone who did not test positive) of Scotland. Cluster analysis will then be used to determine the final definition of the outcome measure for long-COVID. We will then derive, internally and externally validate a prediction model to identify the epidemiological risk factors associated with long-COVID.</AbstractText><AbstractText Label="ETHICS AND DISSEMINATION">The EAVE II study has obtained approvals from the Research Ethics Committee (reference: 12/SS/0201), and the Public Benefit and Privacy Panel for Health and Social Care (reference: 1920-0279). Study findings will be published in peer-reviewed journals and presented at conferences. Understanding the predictors for long-COVID and identifying the patient groups at greatest risk of persisting symptoms will inform future treatments and preventative strategies for long-COVID.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Daines</LastName><ForeName>Luke</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-0564-4000</Identifier><AffiliationInfo><Affiliation>Usher Institute, The University of Edinburgh, Edinburgh, UK luke.daines@ed.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Mulholland</LastName><ForeName>Rachel H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Usher Institute, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vasileiou</LastName><ForeName>Eleftheria</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-6850-7578</Identifier><AffiliationInfo><Affiliation>Usher Institute, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hammersley</LastName><ForeName>Vicky</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-9854-3868</Identifier><AffiliationInfo><Affiliation>Usher Institute, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weatherill</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Usher Institute, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katikireddi</LastName><ForeName>Srinivasa Vittal</ForeName><Initials>SV</Initials><Identifier Source="ORCID">0000-0001-6593-9092</Identifier><AffiliationInfo><Affiliation>MRC/CSO Social &amp; Public Health Sciences Unit, University of Glasgow, Glasgow, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kerr</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Usher Institute, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Public Health Scotland, Glasgow and Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pesenti</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute of Cell Biology, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quint</LastName><ForeName>Jennifer K</ForeName><Initials>JK</Initials><Identifier Source="ORCID">0000-0003-0149-4869</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, National Heart and Lung Institute, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Syed Ahmar</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0001-5672-0443</Identifier><AffiliationInfo><Affiliation>Usher Institute, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Ting</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-4101-4535</Identifier><AffiliationInfo><Affiliation>Usher Institute, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simpson</LastName><ForeName>Colin R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Usher Institute, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Health, Wellington Faculty of Health, Victoria University of Wellington, Wellington, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robertson</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Public Health Scotland, Glasgow and Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Mathematics and Statistics, University of Strathclyde, Glasgow, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheikh</LastName><ForeName>Aziz</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Usher Institute, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_PC_19004</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UU_00022/2</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>SCAF/15/02</GrantID><Acronym>CSO_</Acronym><Agency>Chief Scientist Office</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_PC_19075</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>COV/LTE/20/15</GrantID><Acronym>CSO_</Acronym><Agency>Chief Scientist Office</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064887" MajorTopicYN="N">Observational Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">protocols &amp; guidelines</Keyword><Keyword MajorTopicYN="N">public health</Keyword></KeywordList><CoiStatement>Competing interests: AS is a member of the Scottish Government Chief Medical Officer&#x2019;s COVID-19 Advisory Group and its Standing Committee on Pandemics. He is a member of the UK Government&#x2019;s Risk Stratification Subgroup and Astra-Zeneca's Thrombotic Thrombocytopenic Taskforce. All roles are unremunerated. SVK was co-chair of the Scottish Government&#x2019;s Expert Reference Group on Ethnicity and COVID-19 and a member of the UK Government&#x2019;s Scientific Advisory Group on Emergencies (SAGE) subgroup on ethnicity. All other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>6</Day><Hour>21</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35793922</ArticleId><ArticleId IdType="pmc">PMC9260199</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2021-059385</ArticleId><ArticleId IdType="pii">bmjopen-2021-059385</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization . Who coronavirus disease (COVID-19) Dashboard. Available: https://covid19.who.int/ [Accessed Nov 2021].</Citation></Reference><Reference><Citation>Public Health Scotland . COVID-19 in Scotland daily Dashboard. Available: https://public.tableau.com/profile/phs.covid.19#!/vizhome/COVID-19DailyDashboard_15960160643010/Overview [Accessed Nov 2021].</Citation></Reference><Reference><Citation>World Health Organization . What we know about long-term effects of COVID-19. Available: https://www.who.int/docs/default-source/coronaviruse/risk-comms-updates/update54_clinical_long_term_effects.pdf?sfvrsn=3e63eee5_8 [Accessed Nov 2021].</Citation></Reference><Reference><Citation>Rayner C, Lokugame AU, Molokhia M. Covid-19: prolonged and relapsing course of illness has implications for returning workers. BMJ
2020. 
https://blogs.bmj.com/bmj/2020/06/23/covid-19-prolonged-and-relapsing-course-of-illness-has-implications-for-returning-workers/</Citation></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F, et al. . Persistent symptoms in patients after acute COVID-19. JAMA 2020;324:603&#x2013;5. 10.1001/jama.2020.12603</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Rio C, Collins LF, Malani P. Long-term health consequences of COVID-19. JAMA 2020;324:1723&#x2013;4. 10.1001/jama.2020.19719</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.19719</ArticleId><ArticleId IdType="pmc">PMC8019677</ArticleId><ArticleId IdType="pubmed">33031513</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, et al. . 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021;397:220&#x2013;32. 10.1016/S0140-6736(20)32656-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans RA, McAuley H, Harrison EM, et al. . Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. Lancet Respir Med 2021;9:1275&#x2013;87. 10.1016/S2213-2600(21)00383-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00383-0</ArticleId><ArticleId IdType="pmc">PMC8497028</ArticleId><ArticleId IdType="pubmed">34627560</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D, Khunti K, Nafilyan V. Epidemiology of post-COVID syndrome following hospitalisation with coronavirus: a retrospective cohort study. medRxiv 2021. 10.1101/2021.01.15.21249885</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.15.21249885</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitrani RD, Dabas N, Goldberger JJ. COVID-19 cardiac injury: implications for long-term surveillance and outcomes in survivors. Heart Rhythm 2020;17:1984&#x2013;90. 10.1016/j.hrthm.2020.06.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hrthm.2020.06.026</ArticleId><ArticleId IdType="pmc">PMC7319645</ArticleId><ArticleId IdType="pubmed">32599178</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao L, Jin H, Wang M, et al. . Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 2020;77:683&#x2013;90. 10.1001/jamaneurol.2020.1127</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.1127</ArticleId><ArticleId IdType="pmc">PMC7149362</ArticleId><ArticleId IdType="pubmed">32275288</ArticleId></ArticleIdList></Reference><Reference><Citation>George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir Med 2020;8:807&#x2013;15. 10.1016/S2213-2600(20)30225-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30225-3</ArticleId><ArticleId IdType="pmc">PMC7228727</ArticleId><ArticleId IdType="pubmed">32422178</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajkumar RP. COVID-19 and mental health: a review of the existing literature. Asian J Psychiatr 2020;52:102066. 10.1016/j.ajp.2020.102066</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajp.2020.102066</ArticleId><ArticleId IdType="pmc">PMC7151415</ArticleId><ArticleId IdType="pubmed">32302935</ArticleId></ArticleIdList></Reference><Reference><Citation>ZOE . One in 20 people likely to suffer from &#x2018;Long COVID&#x2019;, but who are they? Available: https://covid.joinzoe.com/post/long-covid [Accessed Nov 2021].</Citation></Reference><Reference><Citation>Office for National Statistics . Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 4 November 2021. Available: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/4november2021 [Accessed Nov 2021].</Citation></Reference><Reference><Citation>NICE guideline . COVID-19 rapid guideline: managing the long-term effects of COVID-19. Available: https://www.nice.org.uk/guidance/ng188 [Accessed Nov 2021].</Citation></Reference><Reference><Citation>NIHR . Living with Covid19 &#x2013; second review. Available: https://evidence.nihr.ac.uk/themedreview/living-with-covid19-second-review/ [Accessed Nov 2021].</Citation></Reference><Reference><Citation>Usher Network for COVID-19 Evidence Reviews . What is the prevalence of the post-COVID-19 syndrome? Available: https://www.ed.ac.uk/files/atoms/files/uncover_028-01_summary_prevalence_of_post_covid-19_syndrome_2april.pdf [Accessed Nov 2021].</Citation></Reference><Reference><Citation>NHS Inform . Longer-Term effects of COVID-19 (long COVID). Available: https://www.nhsinform.scot/illnesses-and-conditions/infections-and-poisoning/coronavirus-covid-19/coronavirus-covid-19-longer-term-effects-long-covid [Accessed Nov 2021].</Citation></Reference><Reference><Citation>Scottish Government . Management and recording of the long-term effects of COVID-19 (long COVID); 2020. https://www.scimp.scot.nhs.uk/wp-content/uploads/CMO-Letter-09.03.21.pdf [Accessed Nov 2021].</Citation></Reference><Reference><Citation>Public Health Scotland . Scottish clinical coding standards. number 27. Available: https://www.isdscotland.org/products-and-services/terminology-services/clinical-coding-guidelines/Docs/Scottish-clinical-coding-standards-Feb-2021-No-27.pdf [Accessed Nov 2021].</Citation></Reference><Reference><Citation>Yelin D, Wirtheim E, Vetter P, et al. . Long-term consequences of COVID-19: research needs. Lancet Infect Dis 2020;20:1115&#x2013;7. 10.1016/S1473-3099(20)30701-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30701-5</ArticleId><ArticleId IdType="pmc">PMC7462626</ArticleId><ArticleId IdType="pubmed">32888409</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall M. The lasting misery of coronavirus long-haulers. Nature 2020;585:339&#x2013;41. 10.1038/d41586-020-02598-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-020-02598-6</ArticleId><ArticleId IdType="pubmed">32929257</ArticleId></ArticleIdList></Reference><Reference><Citation>Rimmer A. Covid-19: impact of long term symptoms will be profound, warns BMA. BMJ 2020;370:m3218. 10.1136/bmj.m3218</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3218</ArticleId><ArticleId IdType="pubmed">32816748</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson CR, Robertson C, Vasileiou E, et al. . Early pandemic evaluation and enhanced surveillance of COVID-19 (EAVE II): protocol for an observational study using linked scottish national data. BMJ Open 2020;10:e039097. 10.1136/bmjopen-2020-039097</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-039097</ArticleId><ArticleId IdType="pmc">PMC7311023</ArticleId><ArticleId IdType="pubmed">32565483</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulholland RH, Vasileiou E, Simpson CR, et al. . Cohort profile: early pandemic evaluation and enhanced surveillance of COVID-19 (EAVE II) database. Int J Epidemiol 2021;50:1064&#x2013;74. 10.1093/ije/dyab028</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyab028</ArticleId><ArticleId IdType="pmc">PMC8195245</ArticleId><ArticleId IdType="pubmed">34089614</ArticleId></ArticleIdList></Reference><Reference><Citation>Scottish Clinical Information Management in Practice (SCIMP) . SCIMP guide to read codes. Available: https://www.scimp.scot.nhs.uk/better-information/clinical-coding/scimp-guide-to-read-codes [Accessed Nov 2021].</Citation></Reference><Reference><Citation>Information Services Division . SMR datasets. General clinical information. Available: https://www.ndc.scot.nhs.uk/Data-Dictionary/SMR-Datasets/General-Clinical-Information/ [Accessed Nov 2021].</Citation></Reference><Reference><Citation>Turas . Turas vaccination management tool. Available: https://learn.nes.nhs.scot/42708/turas-vaccination-management-tool [Accessed Nov 2021].</Citation></Reference><Reference><Citation>NHS24 . Available: https://www.nhs24.scot/111/when-to-phone-111/ [Accessed Nov 2021].</Citation></Reference><Reference><Citation>National Institute for Health and Care Excellence (NICE) . BNF; 2021. https://bnf.nice.org.uk/ [Accessed Nov 2021].</Citation></Reference><Reference><Citation>University of Glasgow . Exploring inequalities in COVID-19 in Scotland. Available: https://www.gla.ac.uk/researchinstitutes/healthwellbeing/research/mrccsosocialandpublichealthsciencesunit/aboutus/covid19/inequalitiescovid/ [Accessed Nov 2021].</Citation></Reference><Reference><Citation>Generation Scotland . CovidLife. Available: https://www.ed.ac.uk/generation-scotland/for-researchers/covidlife [Accessed Nov 2021].</Citation></Reference><Reference><Citation>Clift AK, Coupland CAC, Keogh RH, et al. . Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. BMJ 2020;371:m3731. 10.1136/bmj.m3731</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3731</ArticleId><ArticleId IdType="pmc">PMC7574532</ArticleId><ArticleId IdType="pubmed">33082154</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen AN, Truran D, Kemp M, et al. . Computer-assisted diagnostic coding: effectiveness of an NLP-based approach using SNOMED CT to ICD-10 mappings. AMIA Annu Symp Proc 2018;2018:807&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6371260</ArticleId><ArticleId IdType="pubmed">30815123</ArticleId></ArticleIdList></Reference><Reference><Citation>Koleck TA, Dreisbach C, Bourne PE, et al. . Natural language processing of symptoms documented in free-text narratives of electronic health records: a systematic review. J Am Med Inform Assoc 2019;26:364&#x2013;79. 10.1093/jamia/ocy173</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocy173</ArticleId><ArticleId IdType="pmc">PMC6657282</ArticleId><ArticleId IdType="pubmed">30726935</ArticleId></ArticleIdList></Reference><Reference><Citation>Gower JC. A general coefficient of similarity and some of its properties. Biometrics 1971;27:857&#x2013;71. 10.2307/2528823</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2528823</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousseeuw PJ. Silhouettes: a graphical aid to the interpretation and validation of cluster analysis. J Comput Appl Math 1987;20:53&#x2013;65. 10.1016/0377-0427(87)90125-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0377-0427(87)90125-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunn JC. A fuzzy relative of the ISODATA process and its use in detecting compact well-separated clusters. Journal of Cybernetics 1973;3:32&#x2013;57. 10.1080/01969727308546046</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01969727308546046</ArticleId></ArticleIdList></Reference><Reference><Citation>Moons KGM, Altman DG, Reitsma JB, et al. . Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med 2015;162:W1&#x2013;73. 10.7326/M14-0698</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M14-0698</ArticleId><ArticleId IdType="pubmed">25560730</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>